Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and a consensus price target of $25.57.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $20.02 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market cap of $22.96 billion, a PE ratio of -125.09, a price-to-earnings-growth ratio of 1.10 and a beta of 0.71. The stock has a fifty day moving average of $18.60 and a 200-day moving average of $17.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the company earned $0.61 EPS. The firm’s revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TEVA. Bourgeon Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 100.7% in the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi lifted its stake in Teva Pharmaceutical Industries by 18.5% in the first quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after purchasing an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd boosted its position in Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after buying an additional 19,447 shares during the period. Jump Financial LLC grew its stake in shares of Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock valued at $38,487,000 after buying an additional 134,705 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.